Sophie Gardrat

Dr. Sophie Gardrat


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SGSophie Gardrat
Sophie Gardrat
AHAlexandre Houy
Alexandre Houy
KBKelly Brooks
Kelly Brooks
Nathalie CassouxNathalie Cassoux
Nathalie Cassoux
Raymond BarnhillRaymond Barnhill
Raymond Barnhill
Manuel RodriguesManuel Rodrigues
Manuel Rodrigues
Conjunctival melanoma (ConjMel) is a potentially deadly ocular melanoma, originating from partially sunlight-exposed mucosa. We explored the mutational landscape of ConjMel and studied the correlation with etiological factors. We collected 47 primary ConjMel samples and performed next-generation sequencing of 400 genes. Hotspot mutations in BRAF, NRAS, HRAS, and KIT were observed in 16 (34%), 5 (11%), 2, and 2 cases, respectively. Patients with BRAF and CDKN2A-mutated ConjMel tended to be younger while the NF1-mutated one tended to be older. The eight tumors arising from nevi were enriched in CTNNB1 mutations (63% vs. 8%; Fisher’s exact p-test = 0.001) compared to non-nevi ConjMel and five were devoid of BRAF, RAS, NF1, or KIT mutations, suggesting a specific oncogenic process in these tumors. The two KIT-mutated cases carried SF3B1 mutations and were located on sun-protected mucosa, a genotype shared with genital and anorectal mucosal melanomas. Targetable mutations were observed in ERBB2, IDH1, MET, and MAP2K1 (one occurrence each). Mutational landscape of ConjMel characterizes distinct molecular subtypes with oncogenic drivers common with mucosal and skin melanomas. CTNNB1 mutations were associated with nevus-derived ConjMel. Concomitant KIT/SF3B1 mutations in sun-protected cases suggest a common tumorigenic process with genital and anorectal mucosal melanomas.

27 February 2023 in Annals of Surgery
Verified
Journal Article
Open access
PMpascale mariani
pascale mariani
FBFrancois-Clement Bidard
Francois-Clement Bidard
ARAurore Ba Rampanou
Aurore Ba Rampanou
AHAlexandre Houy
Alexandre Houy
VSVincent Servois
Vincent Servois
SRShufang Renault
Shufang Renault
Objective: We report here the results of a prospective study of circulating tumor DNA (ctDNA) detection in patients undergoing uveal melanoma (UM) liver metastases resection (NCT02849145). Background: In UM patients, the liver is the most common and often only site of metastases. Local treatments of liver metastases, such as surgical resection, have a likely benefit in selected patients. Methods: Upon enrollment, metastatic UM patients eligible for curative liver surgery had plasma samples collected before and after surgery. GNAQ/GNA11 mutations were identified in archived tumor tissue and used to quantify ctDNA by droplet digital polymerase chain reaction which was then associated with the patient’s surgical outcomes. Results: Forty-seven patients were included. Liver surgery was associated with a major increase of cell-free circulating DNA levels, with a peak 2 days after surgery (∼20-fold). Among 40 evaluable patients, 14 (35%) had detectable ctDNA before surgery, with a median allelic frequency of 1.1%. These patients experienced statistically shorter relapse-free survival (RFS) versus patients with no detectable ctDNA before surgery (median RFS: 5.5 vs 12.2 months; hazard ratio=2.23, 95% CI: 1.06–4.69, P=0.04), and had a numerically shorter overall survival (OS) (median OS: 27.0 vs 42.3 months). ctDNA positivity at postsurgery time points was also associated with RFS and OS. Conclusions: This study is the first to report ctDNA detection rate and prognostic impact in UM patients eligible for surgical resection of their liver metastases. If confirmed by further studies in this setting, this noninvasive biomarker could inform treatment decisions in UM patients with liver metastases.

13 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MTMalcy Tarin
Malcy Tarin
NFNémati Fariba
Némati Fariba
Didier DecaudinDidier Decaudin
Didier Decaudin
CCChristine Canbezdi
Christine Canbezdi
BMBenjamin Marande
Benjamin Marande
SASamar Alsafadi
Samar Alsafadi
Uveal Melanoma (UM) is a rare and malignant intraocular tumor with dismal prognosis. Even if radiation or surgery permit an efficient control of the primary tumor, up to 50% of patients subsequently develop metastases, mainly in the liver. The treatment of UM metastases is challenging and the patient survival is very poor. The most recurrent event in UM is the activation of Gαq signaling induced by mutations in GNAQ/11. These mutations activate downstream effectors including protein kinase C (PKC) and mitogen-activated protein kinases (MAPK). Clinical trials with inhibitors of these targets have not demonstrated a survival benefit for patients with UM metastasis. Recently, it has been shown that GNAQ promotes YAP activation through the focal adhesion kinase (FAK). Pharmacological inhibition of MEK and FAK showed remarkable synergistic growth-inhibitory effects in UM both in vitro and in vivo. In this study, we have evaluated the synergy of the FAK inhibitor with a series of inhibitors targeting recognized UM deregulated pathways in a panel of cell lines. The combined inhibition of FAK and MEK or PKC had highly synergistic effects by reducing cell viability and inducing apoptosis. Furthermore, we demonstrated that these combinations exert a remarkable in vivo activity in UM patient-derived xenografts. Our study confirms the previously described synergy of the dual inhibition of FAK and MEK and identifies a novel combination of drugs (FAK and PKC inhibitors) as a promising strategy for therapeutic intervention in metastatic UM.

31 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TRTOULSIE RAMTOHUL
TOULSIE RAMTOHUL
KRKhadija AIT RAIS
Khadija AIT RAIS
SGSophie Gardrat
Sophie Gardrat
Raymond BarnhillRaymond Barnhill
Raymond Barnhill
Sergio Roman-RomanSergio Roman-Roman
Sergio Roman-Roman
VSVincent Servois
Vincent Servois
To evaluate the prognostic implications of melanin quantification assessed by magnetic resonance imaging (MRI) with respect to the clinical, pathological, and genetic features of liver metastases of uveal melanoma (LMUM). This single-center retrospective cohort study included 63 patients eligible for margin-free resection of LMUM between 2007 and 2018. Comparative genomic hybridization of resected liver metastases on microarrays was performed for genetic risk classification. Metastases exhibiting monosomy 3 with any type of gain of chromosome 8 (M3/8g) were considered high-genetic-risk. MRI melanin quantification using the mean T1 signal (mT1s) in liver metastases was assessed quantitatively on preoperative imaging examination and compared to that of gross pathological evaluation. The association between MRI melanin quantification and overall survival (OS) was assessed by multivariate analysis using the Cox proportional hazards model. Gross pathological assessment of melanin content and MRI melanin quantification were strongly correlated (r = 0.8, p < 0.001). Independent prognostic factors associated with OS were disease-free interval ≤ 24 months (HR = 3.1; 95% CI, 1.6–6.0; p < 0.001), high-genetic-risk (HR = 2.2; 95% CI, 1.1–4.8; p = 0.04), mT1s > 1.1 (HR = 2.3; 95% CI, 1.2–4.7; p = 0.019), and complete hepatic resection (HR = 0.3; 95% CI, 0.2–0.7; p = 0.004). In patients with high-genetic-risk, mT1s showed a significant association with OS (HR = 3.7; 95% CI, 1.5–9.3; p = 0.006). The median OS was 17.5 months vs. 27 months for >1.1 and ≤1.1 mT1s tumors, respectively (p = 0.003). We showed that the level of pigmentation in M3/8g LMUM identified two subsets that were correlated with distinct clinical outcomes.

11 October 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
NFNémati Fariba
Némati Fariba
LKLeanne de Koning
Leanne de Koning
DGDavid Gentien
David Gentien
FAFranck Assayag
Franck Assayag
EHEmilie Henry
Emilie Henry
Nathalie CassouxNathalie Cassoux
Nathalie Cassoux
Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we investigated the feasibility of establishing patient-derived xenografts (PDXs) from a patient’s tumor in order to screen for therapies that the patient could benefit from. Samples obtained from 29 primary tumors and liver metastases of uveal melanoma were grafted into SCID mice. PDX models were successfully established for 35% of primary patient tumors and 67% of liver metastases. The tumor take rate was proportional to the risk of metastases. PDXs showed the same morphology, the same GNAQ/11, BAP1, and SF3B1 mutations, and the same chromosome 3 and 8q status as the corresponding patient samples. Six PDX models were challenged with two compounds for 4 weeks. We show that, for 31% of patients with high or intermediate risk of metastasis, the timing to obtain efficacy results on PDX models derived from their primary tumors was compatible with the selection of the therapy to treat the patient after relapse. PDXs could thus be a valid tool (“avatar”) to select the best personalized therapy for one third of patients that are most at risk of relapse.

1 January 2020 in Oncologie
Verified
Journal Article
Open access
SGSophie Gardrat
Sophie Gardrat
VCVincent Cockenpot
Vincent Cockenpot
The pathological examination of ocular tumors has specificities in terms of macroscopic management, microscopic analysis, and molecular examinations requiring special attention. We discuss here the difficulties encountered in the reception in the pathological anatomy laboratory of conjunctival samples, enucleation and orbital exenteration pieces, then detail the diagnostic and theranostic, microscopic and molecular characteristics of ocular tumor pathologies. Conjunctival tumors (epithelial, melanocytic and lymphoid), choroidal tumors (including uveal melanoma) and retinoblastoma are treated. Because of their low frequency and their features, these tumors should be the subject of anatomo-clinical discussions. Résumé:L’examen anatomopathologique des tumeurs oculaires comporte des spécificités en termes de prise en charge macroscopique, d’analyse microscopique, et d’examens moléculaires nécessitant une attention toute particulière. Nous discutons ici les difficultés rencontrées à la réception au laboratoire d’anatomie pathologique des prélèvements conjonctivaux, des pièces d’énucléation et d’exentération orbitaire, puis détaillons les caractéristiques diagnostiques et théranostiques, microscopiques et moléculaires, des pathologies tumorales oculaires. Sont traités les tumeurs conjonctivales (épithéliales, mélanocytaires et lymphoïdes), choroïdiennes (dont le mélanome uvéal) et le rétinoblastome. De par leur faible fréquence et leurs particularités, ces tumeurs doivent faire l’objet de discussions anatomo-cliniques.